The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer

Xinyan Wu, Muhammad Saddiq Zahari, Santosh Renuse, Dhanashree S. Kelkar, Mustafa A. Bharbuiya, Pamela L. Rojas, Vered Stearns, Edward Gabrielson, Pavani Malla, Saraswati Sukumar, Nupam P. Mahajan, Akhilesh Pandey

Research output: Contribution to journalArticle

Abstract

Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers do not express estrogen receptor, progesterone receptor or HER2 receptor and hence are collectively classified as triple negative breast cancer (TNBC). These tumors are often relatively aggressive when compared to other types of breast cancer, and this issue is compounded by the lack of effective targeted therapy. In our previous phosphoproteomic profiling effort, we identified the non-receptor tyrosine kinase TNK2 as activated in a majority of aggressive TNBC cell lines. In the current study, we show that high expression of TNK2 in breast cancer cell lines correlates with high proliferation, invasion and colony forming ability. We demonstrate that knockdown of TNK2 expression can substantially suppress the invasiveness and proliferation advantage of TNBC cells in vitro and tumor formation in xenograft mouse models. Moreover, inhibition of TNK2 with small molecule inhibitor (R)-9bMS significantly compromised TNBC proliferation. Finally, we find that high levels of TNK2 expression in high-grade basal-like breast cancers correlates significantly with poorer patient outcome. Taken together, our study suggests that TNK2 is a novel potential therapeutic target for the treatment of TNBC.

Original languageEnglish (US)
Pages (from-to)2971-2983
Number of pages13
JournalOncotarget
Volume8
Issue number2
DOIs
StatePublished - 2017

Fingerprint

Triple Negative Breast Neoplasms
Protein-Tyrosine Kinases
Breast Neoplasms
Therapeutics
Cell Line
Neoplasms
Progesterone Receptors
Heterografts
Estrogen Receptors

Keywords

  • Phosphorylation
  • TNK2
  • Triple negative breast cancer
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology

Cite this

Wu, X., Zahari, M. S., Renuse, S., Kelkar, D. S., Bharbuiya, M. A., Rojas, P. L., ... Pandey, A. (2017). The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget, 8(2), 2971-2983. https://doi.org/10.18632/oncotarget.13579

The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. / Wu, Xinyan; Zahari, Muhammad Saddiq; Renuse, Santosh; Kelkar, Dhanashree S.; Bharbuiya, Mustafa A.; Rojas, Pamela L.; Stearns, Vered; Gabrielson, Edward; Malla, Pavani; Sukumar, Saraswati; Mahajan, Nupam P.; Pandey, Akhilesh.

In: Oncotarget, Vol. 8, No. 2, 2017, p. 2971-2983.

Research output: Contribution to journalArticle

Wu, X, Zahari, MS, Renuse, S, Kelkar, DS, Bharbuiya, MA, Rojas, PL, Stearns, V, Gabrielson, E, Malla, P, Sukumar, S, Mahajan, NP & Pandey, A 2017, 'The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer', Oncotarget, vol. 8, no. 2, pp. 2971-2983. https://doi.org/10.18632/oncotarget.13579
Wu, Xinyan ; Zahari, Muhammad Saddiq ; Renuse, Santosh ; Kelkar, Dhanashree S. ; Bharbuiya, Mustafa A. ; Rojas, Pamela L. ; Stearns, Vered ; Gabrielson, Edward ; Malla, Pavani ; Sukumar, Saraswati ; Mahajan, Nupam P. ; Pandey, Akhilesh. / The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. In: Oncotarget. 2017 ; Vol. 8, No. 2. pp. 2971-2983.
@article{5c78f186ceed4f8fa25e9aa8e282ecc0,
title = "The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer",
abstract = "Breast cancer is the most prevalent cancer in women worldwide. About 15-20{\%} of all breast cancers do not express estrogen receptor, progesterone receptor or HER2 receptor and hence are collectively classified as triple negative breast cancer (TNBC). These tumors are often relatively aggressive when compared to other types of breast cancer, and this issue is compounded by the lack of effective targeted therapy. In our previous phosphoproteomic profiling effort, we identified the non-receptor tyrosine kinase TNK2 as activated in a majority of aggressive TNBC cell lines. In the current study, we show that high expression of TNK2 in breast cancer cell lines correlates with high proliferation, invasion and colony forming ability. We demonstrate that knockdown of TNK2 expression can substantially suppress the invasiveness and proliferation advantage of TNBC cells in vitro and tumor formation in xenograft mouse models. Moreover, inhibition of TNK2 with small molecule inhibitor (R)-9bMS significantly compromised TNBC proliferation. Finally, we find that high levels of TNK2 expression in high-grade basal-like breast cancers correlates significantly with poorer patient outcome. Taken together, our study suggests that TNK2 is a novel potential therapeutic target for the treatment of TNBC.",
keywords = "Phosphorylation, TNK2, Triple negative breast cancer, Tyrosine kinase",
author = "Xinyan Wu and Zahari, {Muhammad Saddiq} and Santosh Renuse and Kelkar, {Dhanashree S.} and Bharbuiya, {Mustafa A.} and Rojas, {Pamela L.} and Vered Stearns and Edward Gabrielson and Pavani Malla and Saraswati Sukumar and Mahajan, {Nupam P.} and Akhilesh Pandey",
year = "2017",
doi = "10.18632/oncotarget.13579",
language = "English (US)",
volume = "8",
pages = "2971--2983",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "2",

}

TY - JOUR

T1 - The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer

AU - Wu, Xinyan

AU - Zahari, Muhammad Saddiq

AU - Renuse, Santosh

AU - Kelkar, Dhanashree S.

AU - Bharbuiya, Mustafa A.

AU - Rojas, Pamela L.

AU - Stearns, Vered

AU - Gabrielson, Edward

AU - Malla, Pavani

AU - Sukumar, Saraswati

AU - Mahajan, Nupam P.

AU - Pandey, Akhilesh

PY - 2017

Y1 - 2017

N2 - Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers do not express estrogen receptor, progesterone receptor or HER2 receptor and hence are collectively classified as triple negative breast cancer (TNBC). These tumors are often relatively aggressive when compared to other types of breast cancer, and this issue is compounded by the lack of effective targeted therapy. In our previous phosphoproteomic profiling effort, we identified the non-receptor tyrosine kinase TNK2 as activated in a majority of aggressive TNBC cell lines. In the current study, we show that high expression of TNK2 in breast cancer cell lines correlates with high proliferation, invasion and colony forming ability. We demonstrate that knockdown of TNK2 expression can substantially suppress the invasiveness and proliferation advantage of TNBC cells in vitro and tumor formation in xenograft mouse models. Moreover, inhibition of TNK2 with small molecule inhibitor (R)-9bMS significantly compromised TNBC proliferation. Finally, we find that high levels of TNK2 expression in high-grade basal-like breast cancers correlates significantly with poorer patient outcome. Taken together, our study suggests that TNK2 is a novel potential therapeutic target for the treatment of TNBC.

AB - Breast cancer is the most prevalent cancer in women worldwide. About 15-20% of all breast cancers do not express estrogen receptor, progesterone receptor or HER2 receptor and hence are collectively classified as triple negative breast cancer (TNBC). These tumors are often relatively aggressive when compared to other types of breast cancer, and this issue is compounded by the lack of effective targeted therapy. In our previous phosphoproteomic profiling effort, we identified the non-receptor tyrosine kinase TNK2 as activated in a majority of aggressive TNBC cell lines. In the current study, we show that high expression of TNK2 in breast cancer cell lines correlates with high proliferation, invasion and colony forming ability. We demonstrate that knockdown of TNK2 expression can substantially suppress the invasiveness and proliferation advantage of TNBC cells in vitro and tumor formation in xenograft mouse models. Moreover, inhibition of TNK2 with small molecule inhibitor (R)-9bMS significantly compromised TNBC proliferation. Finally, we find that high levels of TNK2 expression in high-grade basal-like breast cancers correlates significantly with poorer patient outcome. Taken together, our study suggests that TNK2 is a novel potential therapeutic target for the treatment of TNBC.

KW - Phosphorylation

KW - TNK2

KW - Triple negative breast cancer

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=85009727189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009727189&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13579

DO - 10.18632/oncotarget.13579

M3 - Article

VL - 8

SP - 2971

EP - 2983

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 2

ER -